Safety and Efficacy of Baricitinib Through 128 Weeks in an Open-label, Longterm Extension Study in Patients with Rheumatoid Arthritis

REFERENCES

1. 1.↵
   1. O’Shea JJ,
   2. Kontzias A,
   3. Yamaoka K,
   4. Tanaka Y,
   5. Laurence A

   . Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis 2013;72 Suppl 2:ii111–5.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Fridman JS,
   2. Scherle PA,
   3. Collins R,
   4. Burn TC,
   5. Li Y,
   6. Li J,
   7. et al.

   Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010;184:5298–307.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Greenwald MW,
   2. Fidelus-Gort R,
   3. Levy R,
   4. Liang J,
   5. Vaddi K,
   6. Williams WV,
   7. et al.

   A randomized dose-ranging, placebo-controlled study of INCB028050, a selective JAK1 and JAK2 inhibitor in subjects with active rheumatoid arthritis [abstract]. Arthritis Rheum 2010;62 Suppl 10:S911.

   OpenUrlCrossRef
4. 4.↵
   1. Tanaka Y,
   2. Emoto K,
   3. Cai Z,
   4. Aoki T,
   5. Schlichting D,
   6. Rooney T,
   7. et al.

   Efficacy and safety of baricitinib in Japanese patients with active rheumatoid arthritis receiving background methotrexate therapy: a 12-week, double-blind, randomized placebo-controlled study. J Rheumatol 2016;43:504–11.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Keystone EC,
   2. Taylor PC,
   3. Drescher E,
   4. Schlichting DE,
   5. Beattie SD,
   6. Berclaz PY,
   7. et al.

   Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate. Ann Rheum Dis 2015;74:333–40.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Taylor P,
   2. Genovese MC,
   3. Keystone E,
   4. Schlichting D,
   5. Beattie S,
   6. Macias W

   . Baricitinib, an oral janus kinase inhibitor, in the treatment of rheumatoid arthritis: safety and efficacy in open-label, long-term extension study [abstract]. Ann Rheum Dis 2013;72 Suppl 3:A65–6.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   1. Winthrop KL,
   2. Yamanaka H,
   3. Valdez H,
   4. Mortensen E,
   5. Chew R,
   6. Krishnaswami S,
   7. et al.

   Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis. Arthritis Rheum 2014;66:2675–84.

   OpenUrlCrossRef
8. 8.↵
   1. Yun H,
   2. Xie F,
   3. Delzell E,
   4. Chen L,
   5. Levitan EB,
   6. Lewis JD,
   7. et al.

   Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. Arthritis Care Res 2015;67:731–6.

   OpenUrlCrossRef
9. 9.↵
   1. Smolen J,
   2. Genovese M,
   3. Takeuchi T,
   4. Hyslop D,
   5. Macias WL,
   6. Rooney TP,
   7. et al.

   Safety profile of baricitinib in patients with active RA: an integrated analysis [abstract]. Ann Rheum Dis 2016;75 Suppl 2:243–4.

   OpenUrl